Skip to content
Screener

Agios Pharmaceuticals AGIO Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Incyte logo
IncyteINCY
$25.56M-11.9%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$785K-39.8%
Disc Medicine logo
Disc MedicineIRON
$967K-33.6%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$301K+90.5%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$1.52M-60.4%
Precigen logo
PrecigenPGEN
11.4%-0.1pp

Other financials

Income statement

See full
Revenue$44.7M+259%
Gross profit$41.7M+288%
Operating income-$110.6M+13.0%
Net income-$100.7M+10.1%
EPS (diluted)-$1.69+12.4%

Balance sheet

See full
Cash & equivalents$99.6M+23.2%
Total debt$31.2M-36.1%
Total equity$1.0B-25.1%
Total assets$1.1B-24.7%

Cash flow

See full
Operating cash flow-$57.3M+25.7%
CapEx$1.2M+38.5%
Free cash flow-$58.5M+25.0%

Valuation

See full
Market cap$1.95B-4.5%
Enterprise value$1.88B-6.4%
P/S19.8×-30.1×

Profitability

See full
Gross margin92%+3.8pp
Operating margin-466.8%-173pp
Net margin-418.2%
FCF margin-371.4%-143pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity0.0×
Current ratio10.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:56 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001439222-26-000118

In arriving at the operating lease liabilities as of June 30, 2026 and December 31, 2025, we applied the weighted-average incremental borrowing rate of 5.7% for both periods over a weighted-average remaining lease term of 1.7 and 2.2 years, respectively.

Item 1. Financial Statements (Unaudited)

FAQ

What is Agios Pharmaceuticals's operating lease ROU assets?
Agios Pharmaceuticals (AGIO) reported operating lease ROU assets of 5.7% in Q2 2026.
How has Agios Pharmaceuticals's operating lease ROU assets changed year-over-year?
Agios Pharmaceuticals's operating lease ROU assets decreased by 0.0% year-over-year, from 5.7% to 5.7%.
What is the long-term trend for Agios Pharmaceuticals's operating lease ROU assets?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's operating lease ROU assets has grown at a -18.5% compound annual growth rate (CAGR), from 8,466,100,000% to 3,045,400,000%.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Agios Pharmaceuticals's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude